2 Top Coronavirus Stocks to Watch in November
You've probably already heard that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently announced the preliminary success of BNT162b2, their joint coronavirus vaccine program. With the world focused on the vaccine race, it's reasonable to suspect that both stocks are no-brainer buys. After all, now that the vaccine is nearly ready to enter mass production, there's no way either company could fail to outperform the market, right?
So far, these expectations haven't been borne out. Both stocks experienced a temporary and beneficial bump after the announcement, which also set off a brief period of exuberant purchasing across the market. But these gains have largely retreated over the following days, compounded by the announcement of Moderna's (NASDAQ: MRNA) better-than-expected vaccine results. It's clear that the vaccine saga isn't over.
Image source: Getty Images.
Source Fool.com
